Key points from article :
Uses the patient’s immune cells as a sort of T-cell training force.
Also targets distinctive proteins on a patient’s own tumor.
Trained dendritic cells to recognize and attack specific malignancy.
In preliminary clinical trial 8 out of 10 patients showed a strong immune response.
50% improved two year survival rate compared to standard chemotherapy alone.
Ovarian cancer is one of the most common types of cancer in women.
Approach may also help in combating solid tumors in different organs.
The study was published in the Science Translational Medicine journal.
